Abbott Laboratories, a diversified healthcare company spanning medical devices, diagnostics, and nutrition products, shows uniformly middling C+-range grades across all four factors. Its stock has pulled back 18.5% over the past year.

The diversified business (not dependent on a single blockbuster drug) provides stability, but also lacks a clear standout growth driver. Valuation (C+, ~35x P/E) remains somewhat elevated even after the pullback, so this is better approached as a stable healthcare diversification holding rather than a value-buy opportunity.